Statistics from Altmetric.com
Systemic lupus erythematosus (SLE) is associated with a highly increased cardiovascular risk. Statins can reduce this risk, but may possess additional anti-inflammatory effects that are relevant for the treatment of SLE. In a preliminary study, we investigated the effects of a 3-month course of rosuvastatin on lipids and markers of inflammation using a randomised cross-over design.
The study was approved by the institutional medical and ethical committee and written informed consent was obtained from all subjects. Based upon a previous, representative study,1 a sample size of 14 patients would be necessary to demonstrate a 25% reduction in C-reactive protein (CRP) levels (power = 80%). A dropout level of 35% (n = 5) was estimated.2 Patients with stable …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.